The interplay between hypertension and COVID-19 could lead to a synergistically increased risk for adverse outcomes due to a decrease in levels of expression of ACE2, due to the use of its of inhibitors that facilitate further entry of SARS-CoV-2 [170]. Here, ACE2 is linked to hypertensive disorder.